{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:16:29Z","timestamp":1793776589420,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-22-140-01-IBCD"],"award-info":[{"award-number":["RSG-22-140-01-IBCD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03971-y","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:12:07Z","timestamp":1740492727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity"],"prefix":"10.1007","volume":"74","author":[{"given":"Chenchen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Shike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charyguly","family":"Annageldiyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cioccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Mineishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WChristopher","family":"Ehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"8","key":"3971_CR1","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S et al (2020) Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 26(8):e177\u2013e182. https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"3971_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/asheducation-2013.1.56","volume":"2013","author":"K van Besien","year":"2013","unstructured":"van Besien K (2013) Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program 2013:56\u201362. https:\/\/doi.org\/10.1182\/asheducation-2013.1.56","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"3971_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443\u2013458. https:\/\/doi.org\/10.1038\/nri3212","journal-title":"Nat Rev Immunol"},{"key":"3971_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0356-4","author":"BR Blazar","year":"2020","unstructured":"Blazar BR, Hill GR, Murphy WJ (2020) Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-020-0356-4","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3971_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri2000","volume":"7","author":"WD Shlomchik","year":"2007","unstructured":"Shlomchik WD (2007) Graft-versus-hostdisease. NatRevImmunol 7(5):340\u2013352. https:\/\/doi.org\/10.1038\/nri2000","journal-title":"NatRevImmunol"},{"issue":"6230","key":"3971_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230):62\u201368. https:\/\/doi.org\/10.1126\/science.aaa4967","journal-title":"Science"},{"issue":"4","key":"3971_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299\u2013308. https:\/\/doi.org\/10.1038\/nrc2355","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3971_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/leu.2012.145","volume":"26","author":"S Anguille","year":"2012","unstructured":"Anguille S, Van Tendeloo VF, Berneman ZN (2012) Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 26(10):2186\u20132196. https:\/\/doi.org\/10.1038\/leu.2012.145","journal-title":"Leukemia"},{"issue":"8","key":"3971_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3109\/14653249.2010.506506","volume":"12","author":"Q Ma","year":"2010","unstructured":"Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y et al (2010) Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056\u20131062. https:\/\/doi.org\/10.3109\/14653249.2010.506506","journal-title":"Cytotherapy"},{"issue":"27","key":"3971_CR10","doi-asserted-by":"publisher","first-page":"44059","DOI":"10.18632\/oncotarget.17212","volume":"8","author":"HJ Sohn","year":"2017","unstructured":"Sohn HJ, Lee JY, Lee HJ, Sohn DH, Cho HI, Kim HJ et al (2017) Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia. Oncotarget 8(27):44059\u201344072. https:\/\/doi.org\/10.18632\/oncotarget.17212","journal-title":"Oncotarget"},{"issue":"50","key":"3971_CR11","doi-asserted-by":"publisher","first-page":"86987","DOI":"10.18632\/oncotarget.18115","volume":"8","author":"S Sandri","year":"2017","unstructured":"Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R et al (2017) Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget 8(50):86987\u201387001. https:\/\/doi.org\/10.18632\/oncotarget.18115","journal-title":"Oncotarget"},{"issue":"9","key":"3971_CR12","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","volume":"106","author":"SA Xue","year":"2005","unstructured":"Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A et al (2005) Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106(9):3062\u20133067. https:\/\/doi.org\/10.1182\/blood-2005-01-0146","journal-title":"Blood"},{"issue":"6","key":"3971_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2014-10-604777","volume":"127","author":"Y Najima","year":"2016","unstructured":"Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, Ochi T et al (2016) Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD\/SCID\/IL2rgKO mice. Blood 127(6):722\u2013734. https:\/\/doi.org\/10.1182\/blood-2014-10-604777","journal-title":"Blood"},{"issue":"7","key":"3971_CR14","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG et al (2019) T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med 25(7):1064\u20131072. https:\/\/doi.org\/10.1038\/s41591-019-0472-9","journal-title":"Nat Med"},{"issue":"174","key":"3971_CR15","doi-asserted-by":"publisher","first-page":"17ra427","DOI":"10.1126\/scitranslmed.3004916","volume":"5","author":"AG Chapuis","year":"2013","unstructured":"Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM et al (2013) Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 5(174):17ra427. https:\/\/doi.org\/10.1126\/scitranslmed.3004916","journal-title":"Sci Transl Med"},{"issue":"6","key":"3971_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41409-018-0383-2","volume":"54","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Sohn HJ, Hong JA, Lee HJ, Sohn DH, Shin CA et al (2019) Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I\/II trial. Bone Marrow Transplant 54(6):903\u2013906. https:\/\/doi.org\/10.1038\/s41409-018-0383-2","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"3971_CR17","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y et al (2017) Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130(18):1985\u20131994. https:\/\/doi.org\/10.1182\/blood-2017-06-791202","journal-title":"Blood"},{"issue":"6","key":"3971_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-002-0284-4","volume":"51","author":"J Galea-Lauri","year":"2002","unstructured":"Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51(6):299\u2013310. https:\/\/doi.org\/10.1007\/s00262-002-0284-4","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3971_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jca.10080","volume":"19","author":"JJ Lee","year":"2004","unstructured":"Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH et al (2004) Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apher 19(2):66\u201370. https:\/\/doi.org\/10.1002\/jca.10080","journal-title":"J Clin Apher"},{"issue":"10","key":"3971_CR20","first-page":"2861","volume":"62","author":"R Spisek","year":"2002","unstructured":"Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL et al (2002) Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 62(10):2861\u20132868","journal-title":"Cancer Res"},{"key":"3971_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1385\/1-59259-862-5:113","volume":"109","author":"IJ de Vries","year":"2005","unstructured":"de Vries IJ, Adema GJ, Punt CJ, Figdor CG (2005) Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med 109:113\u2013126. https:\/\/doi.org\/10.1385\/1-59259-862-5:113","journal-title":"Methods Mol Med"},{"issue":"1","key":"3971_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cellimm.2009.09.003","volume":"260","author":"P Kvistborg","year":"2009","unstructured":"Kvistborg P, Boegh M, Pedersen AW, Claesson MH, Zocca MB (2009) Fast generation of dendritic cells. Cell Immunol 260(1):56\u201362. https:\/\/doi.org\/10.1016\/j.cellimm.2009.09.003","journal-title":"Cell Immunol"},{"issue":"8","key":"3971_CR23","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1182\/blood.V100.8.2858","volume":"100","author":"Y Osugi","year":"2002","unstructured":"Osugi Y, Vuckovic S, Hart DN (2002) Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 100(8):2858\u20132866. https:\/\/doi.org\/10.1182\/blood.V100.8.2858","journal-title":"Blood"},{"key":"3971_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","volume":"5","author":"F Wimmers","year":"2014","unstructured":"Wimmers F, Schreibelt G, Skold AE, Figdor CG, De Vries IJ (2014) Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 5:165. https:\/\/doi.org\/10.3389\/fimmu.2014.00165","journal-title":"Front Immunol"},{"key":"3971_CR25","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3389\/fimmu.2018.03176","volume":"9","author":"TA Patente","year":"2018","unstructured":"Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM (2018) Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol 9:3176. https:\/\/doi.org\/10.3389\/fimmu.2018.03176","journal-title":"Front Immunol"},{"issue":"1","key":"3971_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin M, Bigley V (2018) Human dendritic cell subsets: an update. Immunology 154(1):3\u201320. https:\/\/doi.org\/10.1111\/imm.12888","journal-title":"Immunology"},{"issue":"19","key":"3971_CR27","doi-asserted-by":"publisher","first-page":"E4453","DOI":"10.1073\/pnas.1800550115","volume":"115","author":"L Wu","year":"2018","unstructured":"Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H (2018) Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. Proc Natl Acad Sci USA 115(19):E4453\u2013E4462. https:\/\/doi.org\/10.1073\/pnas.1800550115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"3971_CR28","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1002\/j.1460-2075.1995.tb00098.x","volume":"14","author":"TM Bryan","year":"1995","unstructured":"Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14(17):4240\u20134248","journal-title":"EMBO J"},{"issue":"11","key":"3971_CR29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/nm1197-1271","volume":"3","author":"TM Bryan","year":"1997","unstructured":"Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3(11):1271\u20131274. https:\/\/doi.org\/10.1038\/nm1197-1271","journal-title":"Nat Med"},{"issue":"12","key":"3971_CR30","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC et al (2016) T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res 22(12):3057\u20133066. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2626","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3971_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13045-017-0486-z","volume":"10","author":"L Zhu","year":"2017","unstructured":"Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB et al (2017) Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol 10(1):124. https:\/\/doi.org\/10.1186\/s13045-017-0486-z","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3971_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-018-0069-4","volume":"8","author":"B Jia","year":"2018","unstructured":"Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S et al (2018) Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J 8(3):34. https:\/\/doi.org\/10.1038\/s41408-018-0069-4","journal-title":"Blood Cancer J"},{"key":"3971_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","volume":"190","author":"M Wang","year":"2018","unstructured":"Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G et al (2018) CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol 190:64\u201373. https:\/\/doi.org\/10.1016\/j.clim.2017.08.021","journal-title":"Clin Immunol"},{"issue":"6","key":"3971_CR34","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1172\/JCI32446","volume":"117","author":"CH June","year":"2007","unstructured":"June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6):1466\u20131476. https:\/\/doi.org\/10.1172\/JCI32446","journal-title":"J Clin Invest"},{"issue":"26","key":"3971_CR35","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"303","key":"3971_CR36","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415","journal-title":"Sci Transl Med"},{"issue":"8","key":"3971_CR37","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ et al (2015) CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8):1637\u20131647. https:\/\/doi.org\/10.1038\/leu.2015.52","journal-title":"Leukemia"},{"issue":"6","key":"3971_CR38","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","volume":"32","author":"JC Petrov","year":"2018","unstructured":"Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X et al (2018) Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia 32(6):1317\u20131326. https:\/\/doi.org\/10.1038\/s41375-018-0075-3","journal-title":"Leukemia"},{"issue":"8","key":"3971_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1158\/2326-6066.CIR-15-0215","volume":"4","author":"TD Prickett","year":"2016","unstructured":"Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ et al (2016) Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol Res 4(8):669\u2013678. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0215","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"3971_CR40","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550\u20134557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116","journal-title":"Clin Cancer Res"},{"issue":"4770","key":"3971_CR41","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770):1318\u20131321. https:\/\/doi.org\/10.1126\/science.3489291","journal-title":"Science"},{"issue":"4","key":"3971_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265\u2013277. https:\/\/doi.org\/10.1038\/nrc3258","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3971_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/genes7090061","volume":"7","author":"J Ropio","year":"2016","unstructured":"Ropio J, Merlio JP, Soares P, Chevret E (2016) Telomerase activation in hematological malignancies. Genes (Basel) 7(9):61. https:\/\/doi.org\/10.3390\/genes7090061","journal-title":"Genes (Basel)"},{"issue":"34","key":"3971_CR44","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","volume":"38","author":"X Yuan","year":"2019","unstructured":"Yuan X, Larsson C, Xu D (2019) Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 38(34):6172\u20136183. https:\/\/doi.org\/10.1038\/s41388-019-0872-9","journal-title":"Oncogene"},{"issue":"9","key":"3971_CR45","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1182\/blood.v97.9.2903","volume":"97","author":"J Arai","year":"2001","unstructured":"Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S (2001) Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97(9):2903\u20132907. https:\/\/doi.org\/10.1182\/blood.v97.9.2903","journal-title":"Blood"},{"issue":"16","key":"3971_CR46","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1002\/cncr.30696","volume":"123","author":"HJ Khoury","year":"2017","unstructured":"Khoury HJ, Collins RH Jr, Blum W, Stiff PS, Elias L, Lebkowski JS et al (2017) Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer 123(16):3061\u20133072. https:\/\/doi.org\/10.1002\/cncr.30696","journal-title":"Cancer"},{"issue":"1","key":"3971_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.biochi.2007.07.005","volume":"90","author":"RH Vonderheide","year":"2008","unstructured":"Vonderheide RH (2008) Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 90(1):173\u2013180. https:\/\/doi.org\/10.1016\/j.biochi.2007.07.005","journal-title":"Biochimie"},{"issue":"21","key":"3971_CR48","doi-asserted-by":"publisher","first-page":"10546","DOI":"10.1158\/0008-5472.can-07-2765","volume":"67","author":"SM Domchek","year":"2007","unstructured":"Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR et al (2007) Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Can Res 67(21):10546\u201310555. https:\/\/doi.org\/10.1158\/0008-5472.can-07-2765","journal-title":"Can Res"},{"issue":"1\u20132","key":"3971_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10616-004-5132-2","volume":"45","author":"KP Patel","year":"2004","unstructured":"Patel KP, Vonderheide RH (2004) Telomerase as a tumor-associated antigen for cancer immunotherapy. Cytotechnology 45(1\u20132):91\u201399. https:\/\/doi.org\/10.1007\/s10616-004-5132-2","journal-title":"Cytotechnology"},{"issue":"4","key":"3971_CR50","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/sj.onc.1205074","volume":"21","author":"RH Vonderheide","year":"2002","unstructured":"Vonderheide RH (2002) Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21(4):674\u2013679. https:\/\/doi.org\/10.1038\/sj.onc.1205074","journal-title":"Oncogene"},{"issue":"9","key":"3971_CR51","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1073\/pnas.070560797","volume":"97","author":"B Minev","year":"2000","unstructured":"Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97(9):4796\u20134801. https:\/\/doi.org\/10.1073\/pnas.070560797","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3971_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/1078-0432.CCR-07-4590","volume":"14","author":"L Wenandy","year":"2008","unstructured":"Wenandy L, Sorensen RB, Sengelov L, Svane IM, Thor Straten P, Andersen MH (2008) The immunogenicity of the hTERT540\u2013548 peptide in cancer. Clin Cancer Res 14(1):4\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4590","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3971_CR53","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3892\/or.2012.2036","volume":"28","author":"MH Lu","year":"2012","unstructured":"Lu MH, Liao ZL, Zhao XY, Fan YH, Lin XL, Fang DC et al (2012) hTERT-based therapy: a universal anticancer approach (Review). Oncol Rep 28(6):1945\u20131952. https:\/\/doi.org\/10.3892\/or.2012.2036","journal-title":"Oncol Rep"},{"issue":"7","key":"3971_CR54","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","volume":"109","author":"BJ Chen","year":"2007","unstructured":"Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF et al (2007) Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 109(7):3115\u20133123. https:\/\/doi.org\/10.1182\/blood-2006-04-016410","journal-title":"Blood"},{"issue":"4","key":"3971_CR55","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2003-08-2987","volume":"103","author":"BJ Chen","year":"2004","unstructured":"Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ (2004) Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 103(4):1534\u20131541","journal-title":"Blood"},{"key":"3971_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.molimm.2016.07.012","volume":"77","author":"YS Mohamed","year":"2016","unstructured":"Mohamed YS, Bashawri LA, Vatte C, Abu-Rish EY, Cyrus C, Khalaf WS et al (2016) The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation. Mol Immunol 77:79\u201388. https:\/\/doi.org\/10.1016\/j.molimm.2016.07.012","journal-title":"Mol Immunol"},{"key":"3971_CR57","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.2147\/CMAR.S205296","volume":"11","author":"L Xue","year":"2019","unstructured":"Xue L, Hu Y, Wang J, Liu X, Wang X (2019) T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. Cancer Manag Res 11:6467\u20136476. https:\/\/doi.org\/10.2147\/CMAR.S205296","journal-title":"Cancer Manag Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03971-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03971-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03971-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:19:12Z","timestamp":1743067152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03971-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3971"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03971-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hua Cheng is the founder for ImmuCision Biotherapeutics, LLC, which develops DC technology for profit. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"117"}}